SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells
Author:
Affiliation:
1. Department of Pharmacy, Anhui No.2 Provincial People’s Hospital, Hefei, China;
2. Research Department, The First Affiliated Hospital of USTC, Hefei, China
Publisher
Informa UK Limited
Subject
Pharmaceutical Science,Biomedical Engineering,General Medicine,Medicine (miscellaneous),Biotechnology
Link
https://www.tandfonline.com/doi/pdf/10.1080/21691401.2019.1646748
Reference23 articles.
1. Lung cancer: Biology and treatment options
2. EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
3. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
4. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches;Cancers;2023-11-13
2. FoxO3a Sensitizes NSCLC Cells to EGFR Tyrosine Kinase Inhibitor Treatment Through Inhibiting PDK4 Expression and Glycolysis;2023
3. The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review;Translational Lung Cancer Research;2022-06
4. EMT, Stemness, and Drug Resistance in Biological Context: A 3D Tumor Tissue/In Silico Platform for Analysis of Combinatorial Treatment in NSCLC with Aggressive KRAS-Biomarker Signatures;Cancers;2022-04-27
5. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials;Pharmacology & Therapeutics;2022-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3